Onconetix, Inc., a pharmaceutical company, announced significant changes to its executive team, including the departure of its Chief Financial Officer (CFO) and the appointment of an interim replacement. Bruce Harmon resigned from his role as CFO effective immediately on June 8, 2024. The company stated that Mr. Harmon's departure was followed by a release agreement providing him with two months of severance payment.
Following this departure, Onconetix appointed Karina M. Fedasz as the Interim CFO on Monday. Ms. Fedasz, 51, brings over two decades of experience in financial management, capital raising, and strategic planning. Her diverse background includes roles in business development, as well as CFO positions in various industries ranging from media to biotech.
Prior to joining Onconetix, Ms. Fedasz offered her expertise to clients including a not-for-profit organization and an early-stage company focused on artificial intelligence and health tracking from January 2023 to June 2024. She also served as Head of Business Development at Evofem Biosciences (OTC:EVFM) and managed the initial public offering for IDW Media Holdings.
In addition to Ms. Fedasz's appointment, Onconetix has engaged CFO Squad LLC for certain accounting services starting June 7, 2024. The company has not yet disclosed the compensatory arrangements for Ms. Fedasz, indicating that the Compensation Committee of the Board of Directors will determine these at a later date.
Ms. Fedasz holds an MBA from Columbia Business School and a BA from the University of California, Los Angeles. She also possesses an inactive CPA license in California. Onconetix highlighted that there are no familial relationships between Ms. Fedasz and any of the company's directors or executive officers, nor does she have any material interest in transactions requiring disclosure.
The information in this article is based on a press release statement from Onconetix, Inc.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.